Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance

Molecular Cell

Volumn 16, Issue 3, 2004, Pages 425-438

  He, Bin ^a,b   Gampe Jr , Robert T ^c   Kole, Adam J ^c,d   Hnat, Andrew T ^a   Stanley, Thomas B ^c   An, Gang ^c   Stewart, Eugene L ^c   Kalman, Rebecca I ^a   Minges, John T ^a   Wilson, Elizabeth M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c GLAXOSMITHKLINE   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CRYSTAL STRUCTURE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HYPOTHESIS; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MOTIF; RECEPTOR BINDING; TRANSACTIVATION;

AMINO ACID MOTIFS; BINDING SITES; HUMANS; LIGANDS; MALE; MUTAGENESIS; MUTATION; NUCLEAR PROTEINS; NUCLEAR RECEPTOR COACTIVATOR 2; PEPTIDE FRAGMENTS; PROTEIN INTERACTION MAPPING; RECEPTORS, ANDROGEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 8344226282     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2004.09.036     Document Type: Article

References (54)

1. Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J., McKee D.D., Consler T.G., Parks D.J., Stewart E.L., Willson T.M., et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 110:2002;93-105
2. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., et al. Crystallography and NMR system. a new software suite for macromolecular structure determination Acta Crystallogr. D Biol. Crystallogr. 54:1998;905-921
3. Castro D.S., Arvidsson M., Bondesson Bolin M., Perlmann T. Activity of the Nurr1 carboxyl-terminal domain depends on cell type and integrity of the activation function 2. J. Biol. Chem. 274:1999;37483-37490
4. Chang C., Norris J.D., Gron H., Paige L.A., Hamilton P.T., Kenan D.J., Fowlkes D., McDonnell D.P. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries. discovery of peptide antagonists of estrogen receptors alpha an beta Mol. Cell. Biol. 19:1999;8226-8239
5. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology. opening the X-files Science. 294:2001;1866-1870
6. Culig Z., Hobisch A., Cronauer M.V., Cato A.C., Hittmair A., Radmayr C., Eberle J., Bartsch G., Klocker H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 7:1993;1541-1550
7. Darimont B.D., Wagner R.L., Apriletti J.W., Stallcup M.R., Kushner P.J., Baxter J.D., Fletterick R.J., Yamamoto K.R. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 12:1998;3343-3356
8. Gampe R.T. Jr., Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., Kliewer S.A., Willson T.M., Xu E.X. Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell. 5:2000;545-555
9. Gelmann E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 20:2002;3001-3015
10. Glass C.K., Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:2000;121-141
11. Gregory C.W., He B., Johnson R.T., Ford O.H., Mohler J.L., French F.S., Wilson E.M. A mechanism for androgen receptor mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61:2001;4315-4319
12. Gregory C.W., Fei X., Ponguta L.A., He B., Bill H.M., French F.S., Wilson E.M. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J. Biol. Chem. 279:2004;7119-7130
13. He B., Wilson E.M. Electrostatic modulation of steroid receptor recruitment of the LXXLL and FXXLF motifs. Mol. Cell. Biol. 23:2003;2135-2150
14. 2-terminal domain. J. Biol. Chem. 274:1999;37219-37225
15. 2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 275:2000;22986-22994
16. 2- and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J. Biol. Chem. 276:2001;42293-42301
17. 2- and carboxyl-terminal interaction. J. Biol. Chem. 277:2002;25631-25639. a
18. He B., Minges J.T., Lee L.W., Wilson E.M. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J. Biol. Chem. 277:2002;10226-10235. b
19. Heery D.M., Kalkhoven E., Hoare S., Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 387:1997;733-736
20. Hong H., Kohli K., Trivedi A., Johnson D.L., Stallcup M.R. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc. Natl. Acad. Sci. USA. 93:1996;4948-4952
21. Hsu C.L., Chen Y.L., Yeh S., Ting H.J., Hu Y.C., Lin H., Wang X., Chang C. The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs. J. Biol. Chem. 278:2003;23691-23698
22. Huang N., vom Baur E., Garnier J.M., Lerouge T., Vonesch J.L., Lutz Y., Chambon P., Losson R. Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J. 17:1998;3398-3412
23. Huang W., Shostak Y., Tarr P., Sawyers C., Carey M. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J. Biol. Chem. 274:1999;25756-25768
24. 2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J. Biol. Chem. 273:1998;92-101
25. Li D., Desai-Yajnik V., Lo E., Schapira M., Abagyan R., Samuels H.H. NRIF3 is a novel coactivator mediating functional specificity of nuclear hormone receptors. Mol. Cell. Biol. 19:1999;7191-7202
26. Lu S., Liu M., Epner D.E., Tsai S.Y., Tsai M.J. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol. Endocrinol. 13:1999;376-384
27. Matias P.M., Donner P., Coelho R., Thomaz M., Peixoto C., Macedo S., Otto N., Joschko S., Scholz P., Wegg A., et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 275:2000;26164-26171
28. Metivier R., Stark A., Flouriot G., Hubner M.R., Brand H., Penot G., Manu D., Denger S., Reid G., Kos M., et al. A dynamic structural model for estrogen receptor-alpha activation by ligands, emphasizing the role of interactions between distant A and E domains. Mol. Cell. 10:2002;1019-1032
29. Metzger D., Losson R., Bornert J.M., Lemoine Y., Chambon P. Promoter specificity of the two transcriptional activation functions of the human oestrogen receptor in yeast. Nucleic Acids Res. 20:1992;2813-2817
30. Moras D., Gronemeyer H. The nuclear receptor ligand-binding domain. structure and function Curr. Opin. Cell Biol. 10:1998;384-391
31. Nagpal S., Friant S., Nakshatri H., Chambon P. RARs and RXRs. evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo EMBO J. 12:1993;2349-2360
32. Navaza J. AMoRe. implementation of molecular replacement in AMoRe Acta Crystallogr. D. Biol. Crystallogr. 57:2001;1367-1372
33. Nettles K.W., Sun J., Radek J.T., Sheng S., Rodriguez A.L., Katzenellenbogen J.A., Katzenellenbogen B.S., Greene G.L. Allosteric control of ligand selectivity between estrogen receptors α and β implications for other nuclear receptors Mol. Cell. 13:2004;317-327
34. Newmark J.R., Hardy D.O., Tonb D.C., Carter B.S., Epstein J.I., Isaacs W.B., Brown T.R., Barrack E.R. Androgen receptor gene mutations in human prostate cancer. Proc. Natl. Acad. Sci. USA. 89:1992;6319-6323
35. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 395:1998;137-143
36. Nordzell M., Aarnisalo P., Benoit G., Castro D.S., Perlmann T. Defining an N-terminal activation domain of the orphan nuclear receptor Nurr1. Biochem. Biophys. Res. Commun. 313:2004;205-211
37. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 87:1996;953-959
38. Onate S.A., Tsai S.Y., Tsai M.J., O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 270:1995;1354-1357
39. Otwinowski Z., Minor W. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326
40. Peterziel H., Culig Z., Stober J., Hobisch A., Radmayr C., Bartsch G., Klocker H., Cato A.C. Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int. J. Cancer. 63:1995;544-550
41. Quigley C.A., De Bellis A., Marschke K.B., El-Awady M.K., Wilson E.M., French F.S. Androgen receptor defects. historical, clinical and molecular perspectives Endocr. Rev. 16:1995;271-321
42. Sack J.S., Kish K.F., Wang C., Attar R.M., Kiefer S.E., An Y., Wu G.Y., Scheffler J.E., Salvati M.E., Krystek S.R. Jr., et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. USA. 98:2001;4904-4909
43. Sartorius C.A., Melville M.Y., Hovland A.R., Tung L., Takimoto G.S., Horwitz K.B. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol. Endocrinol. 8:1994;1347-1360
44. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 95:1998;927-937
45. Shulman A.I., Larson C., Mangelsdorf D.J., Rama R. Structural determinants of allosteric ligand activation in RXR heterodimers. Cell. 116:2004;417-429
46. Stanley T.B., Leesnitzer L.M., Montana V.G., Galardi C.M., Lambert M.H., Holt J.A., Xu H.E., Moore L.B., Blanchard S.G., Stimmel J.B. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity. Biochemistry. 42:2003;9278-9287
47. Tan J., Sharief Y., Hamil K.G., Gregory C.W., Zang D.Y., Sar M., Gumerlock P.H., deVere White R.W., Pretlow T.G., Harris S.E., et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol. 11:1997;450-459
48. Thornton J.W. Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. Proc. Natl. Acad. Sci. USA. 98:2001;5671-5676
49. Tremblay G.B., Tremblay A., Labrie F., Giguere V. Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor alpha-beta heterodimeric complex. Mol. Cell. Biol. 19:1999;1919-1927
50. Tsai M.J., O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63:1994;451-486
51. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J., Kallioniemi O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9:1995;401-406
52. Voegel J.J., Heine M.J., Tini M., Vivat V., Chambon P., Gronemeyer H. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J. 17:1998;507-519
53. Webster N.J., Green S., Tasset D., Ponglikitmongkol M., Chambon P. The transcriptional activation function located in the hormone-binding domain of the human oestrogen receptor is not encoded in a single exon. EMBO J. 8:1989;1441-1446
54. Williams S.P., Sigler P.B. Atomic structure of progesterone complexed with its receptor. Nature. 378:1998;392-396